Hot Investor Mandate 1: China-based Private Equity Firm Invests in Biopharma, Medical Devices and Equipment, Diagnostics, HCIT, and R&D Services

28 Dec

A China-based private equity firm with additional offices in Beijing, Shanghai, and Hong Kong with an affiliation to an established Silicon Valley-based investment firm has raised 10 funds to date. The firm invests across several sectors including healthcare. The firm is a full-spectrum investor and will invest from Series A to pre-IPO and PIPE. The firm may also consider buyout and add-on acquisition for its portfolio companies. The firm can invest up to US$100 million per company. Typical investments range from US$5-50 millions. In terms of geography, the firm is China focused, but is also interested in opportunities from US and Europe with a strong China angle.

The firm invests opportunistically in the Healthcare sector and considers each deal on a case-by-case basis. Sectors of interest include biopharma, medical devices and equipment, diagnostics, HCIT, and R&D services that have large market potential. The firm is agnostic to the stage of development. The firm will consider products in pre-clinical up to market approved products.

The firm invests in both private and public companies. The firm invests in Chinese companies as well as US- and Europe-based companies with a China angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: